Business Wire

GIGA-CARBON-NEUTRALITY

11.11.2021 09:54:11 CET | Business Wire | Press release

Share
Clean Energy Trucking Company Giga Carbon Neutrality Is Preparing to Launch 21 Zero-emission Commercial Vehicles by the End Of 2023

Giga Carbon Neutrality (GCN), the clean trucking and technology company, today unveiled a comprehensive range of zero-emission commercial vehicles that it plans to bring to market over the next two years – answering the call from the world’s transportation and logistics operators for a fleet of different options.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005555/en/

GCN will launch 21 different battery-electric and hydrogen fuel-cell powered vehicles by the end of 2023. GCN’s portfolio is configurable to a wide range of commercial use cases and includes a tractor unit, buses and last-mile logistics vehicles. The company’s first prototype hydrogen-fueled tractor unit is currently undergoing advanced road and usability trials in China.

GCN designs its vehicles at a state-of-the-art research and development centre located in Hangzhou , China. GCN has developed its own proprietary hydrogen fuel-cell technology and will source batteries from leading manufacturers initially.

The GCN vehicles are manufactured using lightweight stainless steel and composite materials to improve safety and deliver reductions in weight and energy consumption of at least 10 per cent. The bodies of GCN vehicles are designed to last for 20 years, significantly longer than vehicles from other providers on the market.

GCN is working with public and private sector partners to provide clean energy storage, charging and refueling infrastructure, as well as specialist financing to support the adoption of its zero-emission commercial vehicles globally.

Marty Wade, CEO at Giga Carbon Neutrality, comments: “We are thrilled to give the world its first look at the future of zero-emission commercial transportation.”

“GCN is enabling a carbon-neutral future for some of the world’s most energy-intensive industries, with clean energy vehicles, new technologies and a fueling ecosystem to make running clean, reliable vehicle fleets easy for commercial transportation companies.”

Giga’s initial fleet of zero-emission commercial vehicles

Several GCN vehicles are available to order immediately, with delivery times of between three and 12 months. The company’s initial range includes:

  • The GCN Hydrogen Tractor: A 44-tonne hydrogen fuel-cell truck with a top speed of 90 kph and 580 km range before refueling. Streamlined to minimise wind-resistance, GCN’s ‘heavy truck’ features an ergonomic cab design and a range of intelligent safety systems such as driver fatigue warning systems as standard. A prototype of this vehicle is already on the road in China.
  • The GCN City Bus: A 12-metre transit bus for urban public transport. Capable of carrying up to 95 passengers, GCN’s city bus has a 350 km range on a battery-electric power train and features a monocoque body and collision protection structure offering improved safety for the driver and passengers. This vehicle is designed to meet European Union approved standards for use in its 27 member states.
  • The GCN Pure Electric Minibus: A 6.9-metre battery-electric minibus with an ultra-long wheelbase and flat floor structure to provide capacity for up to 13 passengers. GCN’s minibuses have a 240 km range on a single charge and are already being used on the road in Hong Kong. Autonomous vehicles can also be developed based on this platform.
  • The GCN Electric Logistics Vehicle: An 8-tonne battery-electric truck to support last-mile logistics in urban and rural areas. GCN’s logistics truck has a spacious loading area, can be configured to customer needs and can cover 250 km on a single charge.

About Giga Carbon Neutrality (www.gigacarbonneutrality.com )

Giga Carbon Neutrality is a clean energy trucking and technology company with a supporting ‘Energy-as-a-Service’ (EaaS) offering that makes running clean, reliable vehicle fleets easy for industrial and commercial transportation companies. GCN'S portfolio includes battery-electric and hydrogen fuel cell vehicles, clean energy storage, charging and refueling infrastructure, and specialist financing to support the transition to zero-emission vehicles.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye